MyoKardia Inc. (NASDAQ:MYOK) dropped 4% during trading on Tuesday . The stock traded as low as $15.53 and last traded at $16.25, with a volume of 114,057 shares. The stock had previously closed at $16.93.

MYOK has been the subject of several analyst reports. Zacks Investment Research lowered MyoKardia from a “hold” rating to a “sell” rating in a research note on Friday, April 8th. Wedbush restated an “outperform” rating and issued a $22.00 price objective on shares of MyoKardia in a research note on Thursday, May 12th. Cowen and Company restated a “buy” rating on shares of MyoKardia in a research note on Friday, May 13th. Credit Suisse Group AG restated a “buy” rating and issued a $20.00 price objective (up from $16.00) on shares of MyoKardia in a research note on Tuesday, July 12th. Finally, BMO Capital Markets initiated coverage on MyoKardia in a research note on Wednesday, July 20th. They issued an “outperform” rating and a $28.00 price objective for the company. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $23.50.

The firm’s market capitalization is $438.61 million. The stock has a 50 day moving average price of $14.14 and a 200 day moving average price of $11.22.

MyoKardia (NASDAQ:MYOK) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.32) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.53) by $0.21.

MyoKardia, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.